# This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19

> **NCT05046548** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products** · enrollment: 400 (actual)

## Conditions studied

- Coronavirus Infections
- Vaccine

## Interventions

- **BIOLOGICAL:** Vaccine for intramuscular injection
- **OTHER:** Placebo comparator (without active ingredient) for intramuscular injection

## Key facts

- **NCT ID:** NCT05046548
- **Lead sponsor:** Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-03
- **Primary completion:** 2020-10-15
- **Final completion:** 2021-10-01
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2021-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05046548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05046548, "This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05046548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*